The role of interferon therapy in hepatitis B.

Suppr

超能文献

作者信息

Cooksley W Graham E

机构信息

Department of Medicine, University of Queensland, Royal Brisbane Hospital, Brisbane, Queensland, Australia.

出版信息

MedGenMed. 2004 Mar 18;6(1):16.

PMID:15208528

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1140699/

Abstract

W. Graham E. Cooksley, MD, explores the place that interferon currently holds in the therapeutic armamentarium against hepatitis B.

摘要

相似文献

The role of interferon therapy in hepatitis B.

MedGenMed. 2004 Mar 18;6(1):16.

[Viral hepatitis B/C and HIV. Therapy of double infections].

MMW Fortschr Med. 2003 Apr 28;145 Spec No 1:21-5.

[Antiviral therapy for chronic viral hepatitis B and C].

Nihon Rinsho. 2003 Feb;61 Suppl 2:787-91.

[Hepatitis B (acute and chronic)].

Praxis (Bern 1994). 2004 Jul 28;93(31-32):1227-33; quiz 1234, 1261. doi: 10.1024/0369-8394.93.31.1227.

[Antiviral treatment of chronic hepatitis B with adefovir dipivoxil].

Nihon Rinsho. 2004 Aug;62 Suppl 8:336-9.

Rescue therapy for lamivudine-resistant chronic hepatitis B: comparison between entecavir 1.0 mg monotherapy, adefovir monotherapy and adefovir add-on lamivudine combination therapy.

J Gastroenterol Hepatol. 2010 Aug;25(8):1374-80. doi: 10.1111/j.1440-1746.2010.06381.x.

Long-term efficacy and safety of lamivudine, entecavir, and tenofovir for treatment of hepatitis B virus-related cirrhosis.

Clin Gastroenterol Hepatol. 2013 Jan;11(1):88-94. doi: 10.1016/j.cgh.2012.10.003. Epub 2012 Oct 9.

[Polish multicenter study on safety and efficacy of adefovir dipivoxil in the treatment of lamivudine resistant chronic hepatitis B in adults (HEP 2008)].

Przegl Epidemiol. 2011;65(4):615-20.

Rhabdomyolysis due to lamivudine re-administration in a patient with HBV-related hepatic failure caused by interruption of lamivudine and adefovir.

J Gastrointestin Liver Dis. 2015 Dec;24(4):535-6.

Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B.

J Hepatol. 2008 May;48(5):728-35. doi: 10.1016/j.jhep.2007.12.026. Epub 2008 Feb 29.

引用本文的文献

Schlafens Can Put Viruses to Sleep.

Viruses. 2022 Feb 21;14(2):442. doi: 10.3390/v14020442.

Potential drug development and therapeutic approaches for clinical intervention in COVID-19.

Bioorg Chem. 2021 Sep;114:105016. doi: 10.1016/j.bioorg.2021.105016. Epub 2021 May 25.

Pharmacogenomics of genetic polymorphism within the genes responsible for SARS-CoV-2 susceptibility and the drug-metabolising genes used in treatment.

Rev Med Virol. 2021 Jul;31(4):e2194. doi: 10.1002/rmv.2194. Epub 2020 Nov 17.

The Arabian camel, Camelus dromedarius interferon epsilon: Functional expression, in vitro refolding, purification and cytotoxicity on breast cancer cell lines.

PLoS One. 2019 Sep 6;14(9):e0213880. doi: 10.1371/journal.pone.0213880. eCollection 2019.

Small Molecules and Antibodies for Zika Therapy.

J Infect Dis. 2017 Dec 16;216(suppl_10):S945-S950. doi: 10.1093/infdis/jix406.

Type I interferons induced by endogenous or exogenous viral infections promote metastasis and relapse of leishmaniasis.

Proc Natl Acad Sci U S A. 2017 May 9;114(19):4987-4992. doi: 10.1073/pnas.1621447114. Epub 2017 Apr 24.

miR-146a negatively regulates NK cell functions via STAT1 signaling.

Cell Mol Immunol. 2017 Aug;14(8):712-720. doi: 10.1038/cmi.2015.113. Epub 2016 Mar 21.

Antiviral Potential of a Novel Compound CW-33 against Enterovirus A71 via Inhibition of Viral 2A Protease.

Viruses. 2015 Jun 17;7(6):3155-71. doi: 10.3390/v7062764.

Low-dose interferon-α treatment improves survival and inflammatory responses in a mouse model of fulminant acute respiratory distress syndrome.

Inflammation. 2013 Aug;36(4):812-20. doi: 10.1007/s10753-013-9607-1.

本文引用的文献

Interferon-alpha for HBeAg-positive chronic hepatitis B.

J Hepatol. 2003;39 Suppl 1:S99-105. doi: 10.1016/s0168-8278(03)00154-5.

Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients.

Hepatology. 2003 Dec;38(6):1419-27. doi: 10.1016/j.hep.2003.09.040.

Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B.

J Viral Hepat. 2003 Jul;10(4):298-305. doi: 10.1046/j.1365-2893.2003.00450.x.

EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002: Geneva, Switzerland. Consensus statement (short version).

J Hepatol. 2003 Apr;38(4):533-40. doi: 10.1016/s0168-8278(03)00083-7.

Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B.

N Engl J Med. 2003 Feb 27;348(9):808-16. doi: 10.1056/NEJMoa020681.

Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B.

N Engl J Med. 2003 Feb 27;348(9):800-7. doi: 10.1056/NEJMoa021812.

Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study.

J Hepatol. 2002 Feb;36(2):263-70. doi: 10.1016/s0168-8278(01)00266-5.

Interferon alpha treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B.

Gastroenterology. 2001 Jul;121(1):101-9. doi: 10.1053/gast.2001.25524.

Management of hepatitis B: 2000--summary of a workshop.

Gastroenterology. 2001 Jun;120(7):1828-53. doi: 10.1053/gast.2001.24839.

The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B.

J Hepatol. 2001 Feb;34(2):306-13. doi: 10.1016/s0168-8278(00)00094-5.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验